ArticleOncotarget2018

Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.

Yoshiaki Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.